APC: Inspection prep, part 2

FDA doubles down: Tirzepatide is off shortage

...but that doesn't mean the issue is completely settled. read more →
A couple of state updates

Good news from Alabama, but a problem in Massachusetts read more →
Defending GLP-1 compounding

The latest letters APC's been sending to oppose efforts to restrict compounding read more →
Thumbs-up for FDA crackdown

APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →
A PANS/PANDAS explainer

For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →
What, a year?

In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →
“Simply not a rational approach to regulating an industry”

This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →
Get a cease and desist letter from Verrica?

APC has heard reports from several pharmacies that have received them — here's what to know. read more →

May 21, 2021

Inspection prep, part 2

The good folks at FDA Law Blog have the second in their series “I Hear You Knockin’… Preparing for and Managing DEA Inspections.” This one focuses on the inspectors and what they’re looking for.